Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.1.
- Beam Therapeutics' EPS (Weighted Average and Diluted) rose 598.29% to -$1.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.43, marking a year-over-year decrease of 18037.97%. This contributed to the annual value of -$4.58 for FY2024, which is 16610.14% down from last year.
- Latest data reveals that Beam Therapeutics reported EPS (Weighted Average and Diluted) of -$1.1 as of Q3 2025, which was up 598.29% from -$1.0 recorded in Q2 2025.
- Beam Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $1.91 during Q4 2023, with a 5-year trough of -$3.35 in Q1 2021.
- For the 5-year period, Beam Therapeutics' EPS (Weighted Average and Diluted) averaged around -$1.04, with its median value being -$1.1 (2025).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 27142.86% in 2022, then skyrocketed by 45370.37% in 2023.
- Quarter analysis of 5 years shows Beam Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.91 in 2021, then soared by 40.66% to -$0.54 in 2022, then skyrocketed by 453.7% to $1.91 in 2023, then tumbled by 157.47% to -$1.1 in 2024, then dropped by 0.21% to -$1.1 in 2025.
- Its EPS (Weighted Average and Diluted) was -$1.1 in Q3 2025, compared to -$1.0 in Q2 2025 and -$1.24 in Q1 2025.